$ASNS
ACTELIS NETWORKS INC Stock $asns

$asns Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023070438 Filed on August 24, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$845.0K	$1.896M
YoY Change	-37.31%	-38.46%
Cost Of Revenue	$619.0K	$1.264M
YoY Change	-23.86%	9.06%
Gross Profit	$226.0K	$632.0K
YoY Change	-57.76%	-67.12%
Gross Profit Margin	26.75%	33.33%
Selling, General & Admin	$1.662M	$1.681M
YoY Change	-8.58%	-11.71%
% of Gross Profit	735.4%	265.98%
Research & Development	$691.0K	$669.0K
YoY Change	-4.43%	-1.04%
% of Gross Profit	305.75%	105.85%
Depreciation & Amortization	$10.00K	$6.000K
YoY Change	11.11%	-40.0%
% of Gross Profit	4.42%	0.95%
Operating Expenses	$2.353M	$2.350M
YoY Change	-7.4%	-8.91%
Operating Profit	-$2.127M	-$1.718M
YoY Change	6.03%	161.09%
Interest Expense	$161.0K	$171.0K
YoY Change	-180.1%	-117.17%
% of Operating Profit
Other Income/Expense, Net	$0.00	$296.0K
YoY Change	-100.0%	-129.72%
Pretax Income	-$870.0K	-$1.593M
YoY Change	-60.58%	-3.69%
Income Tax
% Of Pretax Income
Net Earnings	-$867.0K	-$1.593M
YoY Change	-60.72%	-3.69%
Net Earnings / Revenue	-102.6%	-84.02%
Basic Earnings Per Share	-$0.32	-$0.68
Diluted Earnings Per Share	-$0.32	-$0.68
COMMON SHARES
Basic Shares Outstanding	2.708M shares	1.942M shares
Diluted Shares Outstanding	2.686M shares	2.333M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$940.0K	$3.382M
YoY Change	-90.85%	-72.63%
Cash & Equivalents	$682.0K	$2.573M
Short-Term Investments	$250.0K	$809.0K
Other Short-Term Assets	$1.070M	$924.0K
YoY Change	-17.63%	-51.45%
Inventory	$2.698M	$1.808M
Prepaid Expenses
Receivables	$720.0K	$1.759M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$5.415M	$7.873M
YoY Change	-63.28%	-56.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$66.00K	$70.00K
YoY Change	-38.89%	-29.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.680M	$5.631M
YoY Change	285.87%	375.99%
Total Long-Term Assets	$5.743M	$5.701M
YoY Change	263.48%	344.7%
TOTAL ASSETS
Total Short-Term Assets	$5.415M	$7.873M
Total Long-Term Assets	$5.743M	$5.701M
Total Assets	$11.16M	$13.57M
YoY Change	-31.65%	-30.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.190M	$1.918M
YoY Change	156.74%	15.61%
Accrued Expenses	$2.080M	$2.302M
YoY Change	-2.53%	13.85%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.229M	$1.223M
YoY Change	58.17%	59.24%
Total Short-Term Liabilities	$6.631M	$6.716M
YoY Change	18.6%	3.69%
LONG-TERM LIABILITIES
Long-Term Debt	$3.180M	$3.456M
YoY Change	-27.3%	-24.28%
Other Long-Term Liabilities	$25.00K	$32.00K
YoY Change	-51.92%	-47.54%
Total Long-Term Liabilities	$3.585M	$5.469M
YoY Change	-30.67%	2.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.631M	$6.716M
Total Long-Term Liabilities	$3.585M	$5.469M
Total Liabilities	$10.22M	$12.19M
YoY Change	-5.07%	3.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$37.76M	-$36.89M
YoY Change	22.11%	28.48%
Common Stock	$38.60M	$1.000K
YoY Change	3859400.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$838.0K	$1.285M
YoY Change
Total Liabilities & Shareholders Equity	$11.16M	$13.57M
YoY Change	-31.65%	-30.6%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$867.0K	-$1.593M
YoY Change	-60.72%	-3.69%
Depreciation, Depletion And Amortization	$10.00K	$6.000K
YoY Change	11.11%	-40.0%
Cash From Operating Activities	-$2.250M	-$1.234M
YoY Change	12.84%	-50.14%
INVESTING ACTIVITIES
Capital Expenditures	$10.00K	$0.00
YoY Change	-155.56%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$760.0K	$1.011M
YoY Change	25233.33%	429.32%
Cash From Investing Activities	$750.0K	$1.011M
YoY Change	-5100.0%	432.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-190.0K	3.022M
YoY Change	-1.55%	-79.16%
NET CHANGE
Cash From Operating Activities	-2.250M	-1.234M
Cash From Investing Activities	750.0K	1.011M
Cash From Financing Activities	-190.0K	3.022M
Net Change In Cash	-1.690M	2.799M
YoY Change	-23.25%	-77.09%
FREE CASH FLOW
Cash From Operating Activities	-$2.250M	-$1.234M
Capital Expenditures	$10.00K	$0.00
Free Cash Flow	-$2.260M	-$1.234M
YoY Change	14.37%	-50.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	asns	Common Stock Value1 CommonStockValue1		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41375
	dei	Entity Registrant Name EntityRegistrantName	ACTELIS NETWORKS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	52-2160309
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4039 Clipper Court
	dei	Entity Address City Or Town EntityAddressCityOrTown	Fremont
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94538
	dei	City Area Code CityAreaCode	(510)
	dei	Local Phone Number LocalPhoneNumber	545-1045
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	ASNS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2707819	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2573000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3943000	usd
CY2023Q2	us-gaap	Short Term Investments ShortTermInvestments	809000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	1622000	usd
CY2023Q2	us-gaap	Other Restricted Assets Current OtherRestrictedAssetsCurrent	454000	usd
CY2022Q4	us-gaap	Other Restricted Assets Current OtherRestrictedAssetsCurrent	451000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	125000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	125000	usd
CY2023Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1759000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3034000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1808000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1179000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	470000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	678000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	7873000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	10907000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	70000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80000	usd
CY2023Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	492000	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	492000	usd
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2214000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	336000	usd
CY2023Q2	us-gaap	Other Restricted Assets Noncurrent OtherRestrictedAssetsNoncurrent	2213000	usd
CY2022Q4	us-gaap	Other Restricted Assets Noncurrent OtherRestrictedAssetsNoncurrent	2027000	usd
CY2023Q2	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	231000	usd
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	239000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	464000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	726000	usd
CY2023Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	17000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	12000	usd
CY2023Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	5701000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	3912000	usd
CY2023Q2	us-gaap	Assets Assets	13574000	usd
CY2022Q4	us-gaap	Assets Assets	14819000	usd
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	1223000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	553000	usd
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	8000	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	8000	usd
CY2023Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1918000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1781000	usd
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	493000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	484000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	772000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	793000	usd
CY2023Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	996000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	900000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	303000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	445000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1003000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1238000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6716000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6202000	usd
CY2023Q2	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	3456000	usd
CY2022Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	4625000	usd
CY2023Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1576000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	164000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	141000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	237000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	264000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	278000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	32000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	48000	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5469000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5352000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	12185000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	11554000	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	asns	Warrants To Placement Agent WarrantsToPlacementAgent	104000	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1737986	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1737986	shares
CY2023Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	2803774	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	2803774	shares
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	38174000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	36666000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13574000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14819000	usd
CY2023Q2	us-gaap	Revenues Revenues	1896000	usd
CY2022Q2	us-gaap	Revenues Revenues	3081000	usd
	us-gaap	Revenues Revenues	3744000	usd
	us-gaap	Revenues Revenues	4949000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	1264000	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	1159000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	2424000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	2445000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	632000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	1922000	usd
	us-gaap	Gross Profit GrossProfit	1320000	usd
	us-gaap	Gross Profit GrossProfit	2504000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	669000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	676000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1426000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1326000	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	712000	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	837000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1641000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1567000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	969000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1067000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1834000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1702000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	2350000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	2580000	usd
	us-gaap	Operating Expenses OperatingExpenses	4901000	usd
	us-gaap	Operating Expenses OperatingExpenses	4595000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1718000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-658000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3581000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2091000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	171000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	204000	usd
	us-gaap	Interest Expense InterestExpense	351000	usd
	us-gaap	Interest Expense InterestExpense	424000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	296000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-792000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	444000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3778000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1593000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1654000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3488000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6293000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.74
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.72
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-10.9
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2333381	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	952223	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2033747	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	578726	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-19596000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	14000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4639000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-24221000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	14000	usd
CY2022Q2	asns	Stock Issued During Period Value Conversion Of Convertible Preferred Stock To Common Stock Upon Initial Public Offering StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering	5585000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	14675000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	6553000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3600000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	3190000	usd
CY2022Q2	asns	Repurchase Of Common Stock RepurchaseOfCommonStock	15000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1654000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	7757000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3265000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	95000	usd
CY2023Q1	asns	Repurchase Of Common Stock RepurchaseOfCommonStock	-50000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1895000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1415000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	97000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1356000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1593000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1285000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3488000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6293000	usd
	us-gaap	Depreciation Depreciation	13000	usd
	us-gaap	Depreciation Depreciation	20000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-396000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1115000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	223000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	97000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	80000	usd
	asns	Exchange Rate Differences ExchangeRateDifferences	-226000	usd
	asns	Exchange Rate Differences ExchangeRateDifferences	-739000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	192000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	28000	usd
	asns	Changes In Fair Value Related To Convertible Loan ChangesInFairValueRelatedToConvertibleLoan	1648000	usd
	asns	Changes In Fair Value Related To Convertible Note ChangesInFairValueRelatedToConvertibleNote	1753000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	64000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	4000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1275000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	962000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-24000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	82000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	726000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	91000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-208000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	735000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	137000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-261000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-155000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	227000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-36000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	378000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-17000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	136000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2939000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3782000	usd
	asns	Short Term Deposits ShortTermDeposits	810000	usd
	asns	Short Term Deposits ShortTermDeposits	-71000	usd
	asns	Long Term Restricted Bank Deposits LongTermRestrictedBankDeposits	-125000	usd
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	5000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	677000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-87000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3500000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	18712000	usd
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	291000	usd
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	2175000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	50000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	389000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	316000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2780000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16221000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-10000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-739000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	508000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	12352000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4279000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	795000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4787000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13147000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	2573000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	12286000	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	770000	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2214000	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	91000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4787000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13147000	usd
	us-gaap	Interest Paid Net InterestPaidNet	351000	usd
	us-gaap	Interest Paid Net InterestPaidNet	424000	usd
	asns	Issuance Costs Of Common Stock Prefunded Warrants And Warrants IssuanceCostsOfCommonStockPrefundedWarrantsAndWarrants	104000	usd
CY2023Q2	us-gaap	Lines Of Credit Fair Value Disclosure LinesOfCreditFairValueDisclosure	2000000	usd
	asns	Incurred Losses IncurredLosses	3488000	usd
CY2022	asns	Incurred Losses IncurredLosses	10982000	usd
	asns	Negative Cash Flows From Operations NegativeCashFlowsFromOperations	2939000	usd
CY2022	asns	Negative Cash Flows From Operations NegativeCashFlowsFromOperations	7768000	usd
CY2023Q2	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	36890000	usd
	us-gaap	Dividends Cash DividendsCash	3836000	usd
CY2023Q2	us-gaap	Restricted Cash And Investments RestrictedCashAndInvestments	4444000	usd
CY2022Q2	us-gaap	Shares Issued SharesIssued	421250	shares
CY2022Q2	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	46250	shares
CY2022Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	40
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	15400000	usd
	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	1000000	usd
CY2023Q2	asns	Warrants Exercisable Price WarrantsExercisablePrice	29487	shares
	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	50
CY2023Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	145000	usd
	asns	Share Based Compensation Arrangement By Share Based Payment Award Fair Values Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValuesAssumptionsExpectedVolatilityRate	0.54	pure
CY2023Q2	asns	Riskfree Rate RiskfreeRate	0.0301	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	19.5
	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	178377	shares
CY2023Q2	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	2000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-size: 10pt">b)</span></td><td><b>Use of estimates in preparation of financial statements </b></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, fair values of financial instruments, inventory write-offs, as well as in estimates used in applying the revenue recognition policy. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</p>
	us-gaap	Product Warranty Expense ProductWarrantyExpense	8000	usd
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	1576000	usd
CY2022	us-gaap	Product Warranty Expense ProductWarrantyExpense	8000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">e)</span></td><td style="text-align: justify"><b>Concentration of risk</b></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, and trade receivables. Cash and cash equivalents and restricted cash are placed with banks and financial institutions in the United States and Israel.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, present minimal credit risk with respect to those investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company’s trade receivables are derived primarily from telecommunication operators, the Company’s reseller customers and enterprises located mainly in the United States, Europe, and Asia.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Credit risk with respect to trade receivables exists to the full extent of the amounts presented in the condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Accounts receivable have been reduced by an allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company’s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company’s ongoing evaluation of collectability. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company has major customers, representing as follows:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1in"> </td> <td style="width: 0.25in"><span style="font-size: 10pt">1.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Customer A represented 26% and 5% of the Company Trade receivables balance as of June 30, 2023, and December 31, 2022, respectively. </p></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer B represented 14% and 3% of the Company Trade receivables balance as of June 30, 2023, and December 31, 2022, respectively.</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Customer C represented 13% and 29% of the Company Trade receivables balance as of June 30, 2023, and December 31, 2022, respectively. </p></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top"> <td style="width: 1in"></td><td style="width: 0.25in"><span style="font-size: 10pt">4.</span></td><td style="text-align: justify">Customer D represented 0% and 23% of the Company Trade receivables balance as of June 30, 2023, and December 31, 2022, respectively.</td></tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top"> <td style="width: 1in"></td><td style="width: 0.25in"><span style="font-size: 10pt">5.</span></td><td style="text-align: justify">Customer E represented 0% and 10% of the Company Trade receivables balance as of June 30, 2023, and December 31, 2022, respectively.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company does not see any credit risk regarding the major trade receivable balance, as most of the remaining balance was paid off after the balance sheet date.</p>
CY2023Q2	us-gaap	Recorded Unconditional Purchase Obligation Amount Of Maturities And Sinking Fund Requirements RecordedUnconditionalPurchaseObligationAmountOfMaturitiesAndSinkingFundRequirements	10000000	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	969	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	593	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	839	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	586	usd
CY2023Q2	us-gaap	Inventory Gross InventoryGross	1808	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	1179	usd
CY2023Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	97000	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	147000	usd
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-10-31
CY2020Q3	us-gaap	Amount Of Regulatory Assistance Received1 AmountOfRegulatoryAssistanceReceived1	150000	usd
CY2020Q4	asns	New Loan NewLoan	20000000	ils
CY2020Q4	asns	New Loan NewLoan	6000000	usd
CY2020Q4	us-gaap	Financing Receivable Loan In Process FinancingReceivableLoanInProcess	3000000	usd
CY2021Q1	asns	Additional Loan Value AdditionalLoanValue	2000000	usd
	asns	Adjustment Of Warrants Granted For Service AdjustmentOfWarrantsGrantedForService	1500000	usd
CY2021Q4	us-gaap	Investment Company Increase From Payment By Affiliate And Gain Loss From Investment In Violation InvestmentCompanyIncreaseFromPaymentByAffiliateAndGainLossFromInvestmentInViolation	1000000	usd
	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1	1800000	usd
CY2023Q2	us-gaap	Certain Loans Acquired In Transfer Accounted For As Debt Securities Outstanding Balance CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesOutstandingBalance	4522000	usd
CY2023Q2	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	1215000	usd
CY2023Q2	asns	Loan Agreement Value loanAgreementValue	2000000	usd
CY2023Q2	asns	Lessee Operating Lease Liability Payments Due1 Year LesseeOperatingLeaseLiabilityPaymentsDue1Year	3000	ils
CY2023Q2	asns	Lessee Operating Lease Liability Payments Due Two Year LesseeOperatingLeaseLiabilityPaymentsDueTwoYear	9000	ils
CY2023Q2	asns	Lessee Operating Lease Liability Payments Due Three Year LesseeOperatingLeaseLiabilityPaymentsDueThreeYear	9000	ils
CY2023Q2	asns	Lessee Operating Lease Liability Payments Due Four Year LesseeOperatingLeaseLiabilityPaymentsDueFourYear	9000	ils
CY2023Q2	asns	Lessee Operating Lease Liability Payments Due Five Year LesseeOperatingLeaseLiabilityPaymentsDueFiveYear	9000	ils
CY2023Q2	asns	Lessee Operating Lease Liability Payments After Year Five LesseeOperatingLeaseLiabilityPaymentsAfterYearFive	130000	ils
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-12000	ils
CY2023Q2	asns	Total Loans Payments TotalLoansPayments	157000	ils
CY2023Q2	asns	Exchange Rate ExchangeRate	1
CY2023Q2	asns	Exchange Rate ExchangeRate	3.7
	asns	Convertible Note Offering Amount ConvertibleNoteOfferingAmount	3000000	usd
	asns	Convertible Note Offering Percentage ConvertibleNoteOfferingPercentage	0.06	pure
CY2022Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.06	pure
CY2022Q1	asns	Convertible Note Offered ConvertibleNoteOffered	3000000	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	60000	usd
CY2023Q2	us-gaap	Debt Instrument Convertible Liquidation Preference Value DebtInstrumentConvertibleLiquidationPreferenceValue	50000	usd
	asns	Conversion Notes Payable ConversionNotesPayable	1.10	pure
CY2022	asns	Addition Addition	1847000	usd
CY2022	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	1753000	usd
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	3600000	usd
CY2023Q2	us-gaap	Other Expenses OtherExpenses	0	usd
	us-gaap	Other Expenses OtherExpenses	0	usd
CY2022Q2	us-gaap	Other Expenses OtherExpenses	678000	usd
	us-gaap	Other Expenses OtherExpenses	1753000	usd
	us-gaap	Credit Derivative Liquidation Proceeds Percentage CreditDerivativeLiquidationProceedsPercentage	1	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.89
CY2017Q1	asns	Aggregrate Principal Amount AggregratePrincipalAmount	2000000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	4905	usd
CY2022	asns	Change In Fair Value Reported In Statement Of Comprehensive Loss ChangeInFairValueReportedInStatementOfComprehensiveLoss	1648	usd
CY2022	asns	Conversion Of Stock Amount Issued ConversionOfStockAmountIssued	6553	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	682000	usd
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	1648000	usd
CY2022Q4	us-gaap	Servicing Asset At Fair Value Amount ServicingAssetAtFairValueAmount	8000	usd
CY2022Q2	us-gaap	Servicing Asset At Fair Value Amount ServicingAssetAtFairValueAmount	2149000	usd
	us-gaap	Additions To Other Assets Amount AdditionsToOtherAssetsAmount	1972000	usd
	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	-396000	usd
	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	1049000	usd
CY2022Q4	asns	Conversion To The Companys Common Stock ConversionToTheCompanysCommonStock	-3190000	usd
CY2023Q2	us-gaap	Servicing Asset At Fair Value Amount ServicingAssetAtFairValueAmount	1584000	usd
CY2022Q4	us-gaap	Servicing Asset At Fair Value Amount ServicingAssetAtFairValueAmount	8000	usd
CY2023Q2	us-gaap	Other Nonrecurring Income Expense OtherNonrecurringIncomeExpense	-396000	usd
	us-gaap	Other Nonrecurring Income Expense OtherNonrecurringIncomeExpense	-396000	usd
CY2022Q2	us-gaap	Other Nonrecurring Income Expense OtherNonrecurringIncomeExpense	57000	usd
	us-gaap	Other Nonrecurring Income Expense OtherNonrecurringIncomeExpense	1115000	usd
CY2023Q2	us-gaap	Billed Contract Receivables BilledContractReceivables	14300000	usd
CY2023Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	15500000	usd
CY2022	asns	Due Amount DueAmount	221000	usd
	asns	Liability To Pay Royalties LiabilityToPayRoyalties	996000	usd
CY2022	asns	Liability To Pay Royalties LiabilityToPayRoyalties	900000	usd
CY2022Q2	asns	Total Authorized Shares TotalAuthorizedShares	42803774	shares
CY2022Q2	asns	Non Voting Common Stock NonVotingCommonStock	2803774	shares
CY2022Q2	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	10000000	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	7920	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	7920	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	50000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	50000	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10690	shares
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10690	shares
CY2023Q2	asns	Total Gross Amount TotalGrossAmount	3500000	usd
CY2023Q2	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	190000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	754670	shares
CY2023Q2	asns	Prefunded Warrants PrefundedWarrants	754670	shares
CY2023Q2	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.0001
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	1576000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.54	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0349	pure
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	3.7
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Reclassification Adjustment Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterReclassificationAdjustmentTax	396000	usd
CY2023Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	291000	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	66127	shares
	asns	Warrants Exercise Percentage WarrantsExercisePercentage	1.25	pure
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.6313
	asns	Fair Value Of Warrants FairValueOfWarrants	104000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.56	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0329	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	3.58
	asns	Total Offering Costs TotalOfferingCosts	223000	usd
	asns	Issuance Of Common Stocks IssuanceOfCommonStocks	172000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	96458	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.89
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y4M2D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	2315	shares
	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	435	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	40
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	93708	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.81
	asns	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P4Y10M20D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	77759	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.36
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y7D
CY2023Q2	us-gaap	Shares Issued SharesIssued	32100	shares
CY2022Q4	asns	Share Based Compensation Arrangement By Outstanding Numbers ShareBasedCompensationArrangementByOutstandingNumbers	59200	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	16.2
	asns	Share Based Compensation Arrangement By Share Based Payment Options Grants ShareBasedCompensationArrangementByShareBasedPaymentOptionsGrants	32100	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.24
CY2023Q2	asns	Share Based Compensation Arrangements Weighted Average Exercise Price ShareBasedCompensationArrangementsWeightedAverageExercisePrice	-8337	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	29.85
	asns	Share Based Compensation Arrangement By Forfeited ShareBasedCompensationArrangementByForfeited	-1600	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	4.8
CY2023Q2	asns	Share Based Compensation Arrangement By Outstanding Numbers ShareBasedCompensationArrangementByOutstandingNumbers	81363	shares
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	11.65
	asns	Convertible Common Stock Outstanding ConvertibleCommonStockOutstanding	93708	shares
	asns	Convertible Common Stock Outstanding ConvertibleCommonStockOutstanding	86701	shares
	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	4.81
	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	1.21
CY2023Q2	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	81363	shares
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	11.65
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2023Q2	asns	Revenue From Related Parties Amount RevenueFromRelatedPartiesAmount	1896000	usd
CY2022Q2	asns	Revenue From Related Parties Amount RevenueFromRelatedPartiesAmount	3081000	usd
	asns	Revenue From Related Parties Amount RevenueFromRelatedPartiesAmount	3744000	usd
	asns	Revenue From Related Parties Amount RevenueFromRelatedPartiesAmount	4949000	usd
CY2023Q2	asns	Contract With Customer Liability Revenue Recognize ContractWithCustomerLiabilityRevenueRecognize	648000	usd
CY2022Q4	asns	Contract With Customer Liability Revenue Recognize ContractWithCustomerLiabilityRevenueRecognize	673000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-400000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-593000	usd
	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	245000	usd
	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	568000	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	493000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	648000	usd
CY2023Q2	us-gaap	Purchase Obligation PurchaseObligation	493000	usd
	asns	Revenues Percentage RevenuesPercentage	0.10	pure
CY2017Q1	us-gaap	Convertible Debt ConvertibleDebt	26000	usd
CY2022Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	59200	shares
CY2022Q4	asns	Directors Shares Transaction DirectorsSharesTransaction	10000	shares
	asns	Warrant Exercise Price WarrantExercisePrice	75.5
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2023Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent		usd
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Carrying Amount RedeemableNoncontrollingInterestEquityPreferredCarryingAmount		usd
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	asns	Warrants To Placement Agent WarrantsToPlacementAgent		usd
CY2023Q2	asns	Common Stock Value1 CommonStockValue1		usd
CY2023Q2	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued		shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued		shares
CY2023Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding		shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding		shares
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2022Q2	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue		usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
	asns	Changes In Fair Value Related To Convertible Loan ChangesInFairValueRelatedToConvertibleLoan		usd
	asns	Changes In Fair Value Related To Convertible Note ChangesInFairValueRelatedToConvertibleNote		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001141284

Files In Submission

Name	View Source	Status
0001213900-23-070438-index-headers.html	Edgar Link	pending
0001213900-23-070438-index.html	Edgar Link	pending
0001213900-23-070438.txt	Edgar Link	pending
0001213900-23-070438-xbrl.zip	Edgar Link	pending
asns-20230630.xsd	Edgar Link	pending
f10q0623ex31-1_actelis.htm	Edgar Link	pending
f10q0623ex31-2_actelis.htm	Edgar Link	pending
f10q0623ex32-1_actelis.htm	Edgar Link	pending
f10q0623ex32-2_actelis.htm	Edgar Link	pending
f10q0623_actelisnet.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
asns-20230630_cal.xml	Edgar Link	unprocessable
asns-20230630_pre.xml	Edgar Link	unprocessable
asns-20230630_def.xml	Edgar Link	unprocessable
asns-20230630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0623_actelisnet_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ASNS
ACTELIS NETWORKS INC Stock $asns

2023 Q3 Form 10-Q Financial Statement

#000121390023070438 Filed on August 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASNS ACTELIS NETWORKS INC Stock $asns

2023 Q3 Form 10-Q Financial Statement

#000121390023070438 Filed on August 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASNS
ACTELIS NETWORKS INC Stock $asns